Diagnostic and therapeutic use of MIBG in pheochromocytoma and paraganglioma

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 2, 2013, Pages 109-111

  Aktolun, C ^a   Castellani, M R ^b   Bombardieri, E ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; SOMATOSTATIN DERIVATIVE;

COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; HUMAN; PARAGANGLIOMA; PHEOCHROMOCYTOMA; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

3-IODOBENZYLGUANIDINE; ADRENAL GLAND NEOPLASMS; HUMANS; NEUROBLASTOMA; RADIOPHARMACEUTICALS;

EID: 84882297595     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Bravo EL, Gifford RW Jr: Pheochromocytoma: diagnosis, localization and management. N Engl J Med 1984; 311: 1298-1303
2. Rufini V, Calcagni ML, Baum RP: Imaging of Neuroendocrine Tumors. Semin Nucl Med 2006; 36:228-247.
3. Aktolun C, Castellani C: Theranostic role of MIBG in neuroblastoma. Q J Nucl Med Mol Imaging. 2013: 57: 3-5.
4. Bombardiert E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L, Moncayo R, Mortelmans L, Pepe G, Reske SN, Castellani MR, Chiti A. 1311/1231-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. European Association for Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2010;37:2436-46. doi: 10.1007/s00259-010-1545-7.
5. Taïeb D, Timmers HJ, Hindié E, Guillet BA, Neumann HP, Waltz MK, et al: EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2012; 39:1977-1995.
6. Liu B, Zhuang H, Servaes S: Comparison of 123-MIBG and 131-MIBG for imaging of neuroblastoma and other neural crest tumors. Q J Nucl Med Mol Imaging. 2013: 57: 21-28.
7. Parenti G, Zampetti B, Rapizzi E, Ercolino T, Giachè V, Man-nelli M. Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma. J Oncol. 2012;2012:872713. doi: 10.1155/2012/872713. Epub 2012 Jul 17.
8. Castellani MR, Seghezzi S, Chiesa C, Aliberti GL, Maccauro M, Seregni E, Orunesu E, Luksch R, Bombardieri E. (13DI-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy. Q J Nucl Med Mol Imaging. 2010;54:100-13.
9. 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012;39:1266-70.
10. Breeman WAP, de Blois E, Chan HS, Konijnenberg M, Kwekke-boom DJ, Krenning EP: 68Ga-labeled DOTA-peptides and 68Ga-labeled radiopharmaceuticals for positron emission tomography: Current status of research, clinical applications, and future perspectives. Semin Nucl Med 2011; 41:314-321.
11. Carrasquillo JA, Pandit-Taskar N, Chen CC. Radionuclide therapy of adrenal tumors. J Surg Oncol. 2012 Oct 1;106(5):632-42. doi: 10.1002/jSO.23196. Epub 2012 Jun 20.
12. Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, Hörsch D, O'Dorisio MS, O'Dorisiol TM, Howe JR, Cremonesi M, Kwekkeboom DJ. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800-16. doi: 10.1007/s00259-012-2330-6.
13. Zovato S, Kumanova A, Demattè S, Sansovini M, Bodei L, Di Sarra D, Casagranda E, Severi S, Ambrosetti A, Schiavi F, Opocher G, Paganelli G. Peptide receptor radionuclide therapy (PRRT) with 177LU-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL). Horm Metab Res. 2012;44:411-4. doi: 10.1055/S-0032-1311637. Epub 2012 May 7.
14. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini GC, Rubello D, et al: Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumors. Eur J Nucl Med Mol Imaging 2008;35, 1431-8.
15. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B, Eisenhofer G, Martiniova L, Adams KT, Pacak K. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94:4757-67. doi: 10.1210/jc.2009-1248. Epub 2009 Oct 28.
16. Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 1231-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheo-chromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95:2800-10.
17. Rufini V, Treglia G, Castaldi P, Perotti G, Calcagni ML, Corsello SM, Galli G, Fanti S, Giordano A. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun. 2011;32:575-82. doi: 10.1097/MNM. 0b013e328345a340.